Vault CDMS will manage clinical data from a trial involving patients with Barrett’s esophagus and esophageal adenocarcinoma
PLEASANTON, Calif., May 4, 2022 /PRNewswire/ — Veeva systems (NYSE: VEEV) today announced that Lucid Diagnostics Inc. (Nasdaq: LUCD), a commercial-stage cancer prevention medical diagnostics company and majority-owned subsidiary of PAVmed inc. (Nasdaq: PAVM, PAVMZ), selected CDMS Veeva Vault provide electronic data capture (EDC), codingand data cleaning in their upcoming study for EsoGuard in patients undergoing standard screening and management for Barrett’s esophagus or esophageal adenocarcinoma.
Lucid Diagnostics is a medical device innovator that develops products to diagnose and treat conditions of the esophagus, including those resulting from chronic heartburn that can lead to esophageal cancer. The multicenter, prospective, open-label registry study will collect real-world data on the use of EsoGuard tests on specimens collected with EsoCheck from patients at risk for detection of Barrett’s esophagus and/or adenocarcinoma of the ‘esophagus.
“Every research project is unique, and we are honored that Lucid Diagnostics has chosen to partner with Veeva for its critical research,” said Ami Dudzinski Mehr, Vice President of Strategy, Vault CDMS, Veeva MedTech. “Veeva Vault CDMS is designed to handle a wide variety of study requirements and this study is a great example.”
Veeva is proud to support medical technology companies like Lucid Diagnostics with Vault CDMS, a unified data management solution for today’s clinical trials. Learn how Lucid Diagnostics is accelerating study builds and scaling for the future at Veeva MedTech Summit in Minneapolis May 31 – June 2. Industry professionals can register here.
To learn more about Veeva Vault CDMS for medtech, visit: veeva.com/medtech/CDMS
Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems Follow @veevasystems on Twitter: twitter.com/veevasystems
About Lucid Diagnoses
Lucid Diagnostics Inc. (Nasdaq: LUCD) is a commercial-stage cancer prevention medical diagnostics company and a subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid focuses on the millions of patients with gastroesophageal disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. EsoGuard by Lucid® Esophageal DNA test, performed on samples taken in a brief, non-invasive office procedure with its EsoCheck® The esophageal cell collection device is the first and only commercially available diagnostic test capable of serving as a widespread screening tool to prevent cancer and cancer deaths through the early detection of esophageal precancer in patients at risk of GERD. EsoGuard is marketed in the United States as a laboratory developed test (LDT). EsoCheck is marketed in the United States as a 510(k) cleared esophageal cell collection device. EsoGuard, used with EsoCheck, has received FDA Breakthrough Device designation and is undergoing two large, international, active-enrollment, multi-center clinical trials to support FDA PMA approval. Lucid is building a nationwide direct sales and marketing team targeting primary care physicians, gastroenterologists, and consumers, as well as a network of Lucid Testing Centers where patients at risk for GERD can undergo the EsoCheck procedure for EsoGuard testing. For more information, please visit www.luciddx.comfollow Lucid on Twitterand connect with Lucid at LinkedIn. For detailed information about EsoGuard, please visit www.EsoGuard.com and follow us on Twitter, Facebook and instagram.
About Veeva Systems
Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence and customer success, Veeva serves more than 1,000 customers, ranging from the world’s largest pharmaceutical companies to emerging biotechs. As a public benefit company, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.
SOURCE Veeva Systems